Despite positive clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant opposition from PBMs. The companies are typically erecting limitations to reimbursement, including high cost restrictions and PA that restrict patient availability. Market believe that these re… Read More